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Abstract
Cardiomyocyte differentiation overall has been analyzed in vivo and in vitro at the molecular level by homologous recombination, gene
mutation studies, and by transgenics; however, the roles of many signal transduction mechanisms that drive this differentiation process are
still not fully understood. One set of signal transduction components that has been studied in detail in mature, differentiated cardiomyocytes
is the PKC isotype superfamily. However, while the function of each isotype is slowly being uncovered in adult cardiomyocytes, limited
information persists concerning their function in the differentiation process of cardiomyocytes. To begin analyzing the function of specific
PKC isotypes in the differentiation process, we employed an established model for differentiating ES cells into cardiomyocyte-positive
embryoid bodies (EBs) in vitro. RT-PCR, Western analyses, and confocal microscopy all showed that the expression of specific PKC
isotypes was significantly changed as ES cells differentiated into cardiomyocytes. More importantly, by using antagonists specific for each
isotype we found that this change was a final step in the differentiation process. PKC and  downregulation served to promote
differentiation (beating), while upregulation of PKC appeared to amplify differentiation (beating). Finally, melding classical tools (i.e.,
ionic exchange glass beads) with recently developed methods for differentiating ES cells creates a possible novel technique for investigating
differentiation of ES cells into cardiomyocytes as well as other cell types.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Early development of the heart is composed of two major
stages: cardiomyocyte specification/differentiation and
heart morphogenesis. While extensive detail of heart mor-
phogenesis has been described in vivo and in vitro from
experiments involving genetic manipulation, biochemical,
and structural analyses, far fewer in vitro or in vivo inves-
tigations have described what regulates cardiomyocyte dif-
ferentiation. Attributable to this deficit in knowledge is the
difficulty in attaining mammalian embryos at precardio-
myocyte stages as well as analyses of cardiomyocytes from
early heart tubes if procured properly. Recently, however, it
was shown that a model system comprised of embryonic
stem cells faithfully recapitulates cardiomyocyte differenti-
ation if the ES cells are cultured under the correct conditions
(Hescheler et al., 1997; Metzger et al., 1996; Meyer et al.,
2000; Wobus et al., 1991; Xu et al., 1998). This highly
reliable model system has made it possible to investigate the
molecular pathways that control specification and differen-
tiation of once pluripotent, nonbeating ES cells into nascent,
beating cardiomyocytes. Utilizing this model system, the
number of genetic manipulation studies to determine genes
that regulate ES cell differentiation has risen dramatically
over the past few years. Many of these investigations have
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not only described gene expression (Hescheler et al., 1997;
Lim et al., 2001; Oyamada et al., 1996), but also shown the
result of gene function upon suppression by homologous
recombination (Fassler et al., 1996; Gallicano et al., 2001;
Xu et al., 1998). Despite much of this highly important
work, however, few studies have investigated in detail the
posttranslational role of the genes being studied, especially
the role of signal transduction mechanisms in the differen-
tiation process.
One major set of signal transduction components that
have been investigated in detail in adult, differentiated car-
diomyocytes are the PKC isotypes, with emphasis on PKC
, 1/2, , and  in the mouse (Johnson et al., 1996; Roman
et al., 2001). Upregulation of these particular PKC isotypes
within human and mouse heart tissue has been closely
associated with certain heart diseases such as hypertrophy,
heart failure, and ischemia (Gray et al., 1997; Mizukima et
al., 2000; Muth et al., 2001; Rouet-Benzineb et al., 1996).
PKC isotypes come in three flavors: classical, novel, and
atypical. Classical PKCs (alpha-, beta-1/2, and gamma-)
are reliant upon 1,2-diacyl-sn-glycerol (DG), acidic mem-
brane phospholipids, and calcium. Novel PKCs (delta-,
epsilon-, eta-, theta-, and mu-	) rely on DG and acidic
phospholipids, but not calcium, while acidic phospholipids
appear to be all that is necessary for activation of atypical
PKCs (zeta-, iota-
, and lambda-).
Virtually all tissue types have been shown to contain a
diverse array of PKC isotypes, each of which has been
implicated in regulating certain cellular events. However,
when a cell uses its PKC isotypes in specific combinations
to drive cellular functions, the regulatory power of this
superfamily can become extensive (Gallicano et al., 1993,
1995, 1997; Nishizuka, 1992; Oyamada et al., 1996; Pauken
and Capco, 2000; Schreiber et al., 2001). Pioneering the
PKC field of research in the heart, the Mochly–Rosen lab-
oratory has assigned functions for each isotype of PKC in
adult and neonatal cardiomyocytes. However, as each iso-
type function is uncovered in adult-derived cardiomyocytes,
limited information persists concerning their function in
early cardiac development, especially during the differenti-
ation process of cardiomyocytes. Based on the fact that
specific PKC isotypes regulate certain functions in adult
cardiomyocytes, we hypothesized that distinct regulation of
these components must occur during cardiomyocyte differ-
entiation in order to successfully drive pluripotent ES cells
down the cardiomyocyte differentiation pathway (i.e., into
beating cells). To test this hypothesis, we analyzed embry-
oid bodies (EBs) that had been induced to differentiate
along the cardiac pathway. Specific stages of EB differen-
tiation were analyzed by using highly specific pharmaco-
logical, biochemical, and microscopic analyses. We found
that inhibition of PKC and- in cooperation with increased
PKC protein and its activation are critical, final, spatio-
temporal steps involved in the differentiation process of
cardiomyocytes from ES cells.
Materials and methods
ES cell culture and production of cardiomyocytes
R1-type ES cells were grown on mitomycin C-treated
feeder layers consisting of mouse primary embryonic fibro-
blasts in DMEM medium containing 15% KSR (knockout
serum replacement; GIBCO), 1 nonessential amino acids,
2.0 mM glutamine, 1000 units/ml leukemia inhibitory factor
(LIF), and 100 	M 2-mercaptoethanol. This media inhibits
differentiation of ES cells and is used until differentiation is
induced. For differentiation of ES cells, embryoid bodies
(EBs) are generated by the hanging drop method (Metzger
et al., 1994). Once EBs were generated, they were incubated
in DMEM with 15% fetal bovine serum (FBS) for 2 days in
the absence of LIF, followed by incubation in suspension
for 5 days. At the end of incubation day 5, individual EBs
were placed into a single well of a 24-well plate. Rhythmic
beating of EBs indicating cardiac muscle differentiation was
monitored by daily inspection of cultures using phase mi-
croscopy.
Beating areas were isolated from nonbeating areas fol-
lowing the procedure of Maltsev et al. (1994). Briefly,
beating areas were isolated by using a microscalpel (Fine
Science Tools, Foster City, CA). Any nonbeating cells as-
sociated with the beating area were trimmed away. Ten
beating and nonbeating areas of similar size were separated
and briefly washed in DEPC-treated (RNase-free) phos-
phate-buffered saline (PBS). Subsequent EBs were ana-
lyzed for cardiomyocyte (or alternative tissue) formation by
RT-PCR, DIC microscopy, immunofluorescence, and West-
ern blot.
Reagents
Myr-PKC pseudosubstrates were purchased from Bi-
omol (Plymouth Meeting, PA). Each inhibitor was dis-
solved in DMSO at 100 immediately prior to use. Unused
inhibitor was aliquoted into Eppendorf tubes and stored at
80°C. Antibodies against PKC isotypes were purchased
from BD Transduction Laboratories (San Diego, CA) and
Santa Cruz Biotech Inc. (CA). Antibodies against cardiac
troponin were purchased from Santa Cruz Inc. Anti-cardiac
actin was purchased from American Research Products
(Belmont, MA) and anti-tubulin from Sigma Inc. (St. Louis,
MO).
RT-PCR
Isolated beating or nonbeating areas (each comprised of
1  103 cells) from EBs were immediately placed into
Trizol reagent (Life Technologies Inc., Gaithersburg, MD)
to isolate RNA. Yeast tRNA (100 ng) was added to each
tube to act as a carrier. RT-PCR was carried out by using the
Superscript II RT-PCR Kit (Life Technologies, Inc.) in
20-	l reactions at 42°C for 60 min. cDNA was synthesized
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by using either oligo(dT) primer or specific PKC primers.
Two microliters of the RT reaction were then pipetted into
a 20-	l PCR mixture containing 1 PCR buffer II, 40 ng of
each primer, optimal concentration of MgCl2, 0.2 mM
dNTPs, and 2 U of Taq polymerase. The DNA template was
denatured at 94°C, followed by amplification using the
following parameters: 94°C for 20 s, 59°C for 45 s, and
72°C for 1 min, for 35 cycles. Control RT-PCRs were run
for each batch of mRNA. First, no RT was used in concur-
rent reactions to determine whether contaminating DNA
was present. Second, when possible primers were generated
from two different exons. The rationale for this approach is
that amplification of contaminating genomic DNA would
result in a PCR product with a molecular weight much
higher than a PCR product amplified from cDNA because
intronic sequences would be included in the amplification.
Third, tubulin primers were used as a positive control for all
PCRs.
Primer sequences for PKC , , , , , , and 	 can be
found in Pauken and Capco (2000). Primer sequences for ,

, and  were obtained from mouse PKC cDNA located in
GenBank: PKC  5 primer, CAAAATCTGCGAGGCCGT-
GAGG; 3 primer, GCATCCGCTCCCTAAACACTCG, 310
bp; PKC 
 5 primer, GTCGGGCTGCATTCTTGCTTCCAG;
3 primer, TCCTTCCTTACACATGCCGTAGAG, 260 bp;
and PKC  5 primer, CAAGTGGAACAGATTTCTCAA-
GAC; 3 primer, CACTGCCCTTTACTTTCCTCTGCCTTG,
275 bp. Each primer set could amplify the proper size band
from 1:1000 dilution of cDNA product from an RT reaction of
1 	g total RNA isolated from pluripotent ES cells, adult heart
cells, and/or brain tissue. Ten-microliter aliquots of each PCR
product were electrophoresed on a 2% agarose gel and visu-
alized by using ethidium bromide.
Sequences for heart-specific primers were obtained from
Xu et al. (1998) and Fassler et al. (1996). The size for atrial
natriuretic factor (ANF) was 203 bp, myosin light chain 2v
(MLC2V) 189 bp, -cardiac myosin heavy chain (CMH)
301 bp, and 1-subunit of the L-type Ca2 channel
(CaChan) 200 bp. RT-PCR was performed with similar
parameters as described above for PKC isotypes. RNAs
from five independent experiments were analyzed. Heart
tube RNA from E8.5 day embryos and water were used as
positive and negative controls, respectively.
Western blot analysis
Isolated beating or nonbeating areas (each comprised of
1  103 cells) from EBs were immediately placed into
sample buffer (62.5 mM Tris–HCl, pH 6.8, 2% SDS w/v, 1
mM -mercaptoethanol, 10% glycerol). Samples were
boiled for 5 min and loaded onto 10% polyacrylamide gels
with molecular wt. markers and separated by SDS–PAGE.
Proteins were transferred to PVDF membrane and blocked
with blotto (5% dry milk in PBS, pH 7.4, with 0.1% Tween
20) at room temperature (rt). The blots were challenged with
primary antibody at dilutions of 1/500–1/1000 in blotto
overnight at 4°C, followed by washing three times with
PBT (1  PBS  0.1% Tween 20) at rt and challenge with
appropriate secondary antibody conjugated to horseradish
peroxidase (Pierce Inc., Rockford, IL). As a positive con-
trol, cell samples provided with the antibodies were always
loaded in a subsequent lane to verify the size of the PKC
isotype within EBs. Each stage of beating or nonbeating
areas was analyzed three to five times.
Analysis of beating areas
Beating activity of cultured EBs containing cardiomyo-
cytes was measured by edge-detection using videomicros-
copy. Briefly, photodiode sensors attached to a monitor
screen showing beating cells acquired beating-related data.
The entire microscope was enclosed in a temperature-con-
trolled (37°C) incubation chamber fed with 5% CO2/95%
air to maintain constant pH. The photodiode sensor infor-
mation was filtered and relayed to a PC equipped with a
National Instruments data acquisition board and LabView
4.0 processing software. Parallel outputs were also directed
to a Gould TA550 chart recorder, videocassette recorder,
and an oscilloscope. The LabView software was pro-
grammed to measure rate (interval between each beat) and
rhythmicity (variability of the interval between beats). The
data were continuously acquired and stored to disk for later
analysis.
Immunofluorescence analysis
Differentiated EBs that had been grown on coverslips
were fixed for 20 min in PBS containing 2.0% paraformal-
dehyde, followed by permeabilization in 1.0% Tween 20 in
PBS. After washing in 5 mM glycine in PBS for 1 h, EBs on
coverslips were transferred to intracellular buffer (ICB; Gal-
licano et al., 1997; 100 mM KCl, 5 mMMgCl2, 2 mM
EGTA, 20 mM Hepes, pH 6.8), containing 1.0% protein
blocking agent included in the Mouse on Mouse immuno-
cytochemistry kit (M.O.M. kit; Vector Labs, Burlingame,
CA) for 30 min at rt. EBs were then placed into blocking
buffer containing primary antibodies diluted 1:100 and in-
cubated either at rt for 1 h or overnight at 4°C. EBs were
washed in ICB three times, followed by incubation in block-
ing buffer containing the appropriate secondary antibody,
and analyzed using a Zeiss confocal microscope.
Application of ionic beads
Application of PKC inhibitors to specific areas within
EBs was accomplished by using AG ion exchange resins
(Noveen et al., 1995; Biorad, Inc., Hercules, CA). AG 1-X4
hydroxide beads with a diameter of 63–150 	m were
soaked for 1 h in myr-PKC-pseudosubstrate, which has a
net charge of 2. They were briefly washed in DMEM and
spread onto EBs so that10–15 beads were in contact with
cells. Within 2–3 h, ES cells would attach and anchor beads
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into place. AG 50W-X4 beads with a diameter of 75–150
	m were soaked for 1 h in myr-PKC pseudosubstrate,
which has a net charge of 6. Ten to fifteen beads were
spread onto EBs, with ES cells anchoring the beads into
place after 2– 3 h of culture. Control anionic and cationic
beads were soaked in plain DMEM or 1% DMSO for 1 h.
Statistics
All experimental groups in this study were replicated a
minimum of three times. For display of data, each point on
a graph represents a mean  standard error of the mean
(SEM; represented by error bars) for an experimental group
or observation. To determine statistical differences between
experimental groups or observation points, we applied the
ANOVA statistical software package provided by Microsoft
Excel (modified t test). Graphs and tables showing percent-
ages were analyzed two ways: by pooling all data together
for a given treatment group, or by obtaining a percentage for
each experiment and producing an SEM for all experiments.
Results
PKC isotype gene expression differs in beating and
nonbeating areas within embryoid bodies
Differentiation of ES cells into cardiomyocytes first re-
quires their formation into embryoid bodies (EBs) by grow-
ing them in hanging drop cultures (Hescheler et al., 1997;
Wobus et al., 1991). After 2 days in hanging drops, EBs are
placed into suspension for 5 days, after which they are
plated into individual wells of a 24-well plate. Beating
commences in distinct areas within EBs on average 2 days
later (culture day 7; 5 days in suspension  2 days in tissue
culture plates), peaking at culture day 10 in our hands (Fig.
1A and B). Beating areas were surgically isolated from
nonbeating areas by using a microscalpel. A distinct demar-
cation between beating and nonbeating areas was evident at
high magnification by using a dissecting microscope (Fig.
1A and B shows best focal plane for observing beating,
while the inset shows the best focal plane for demarcation;
arrows). Any potentially contaminating nonbeating cells in
an isolated beating area were further dissected away by
using the microscalpel and microforceps (Fine Science
Tools, Foster City, CA) until only beating cells were
present. As a further control, heart-specific gene expression
in cultured EBs using RT-PCR was routinely performed.
While heart-specific genes were always expressed in beat-
ing areas, virtually none were expressed in pluripotent ES
cells (capable of forming chimeric mice). Nonbeating areas
did show positive expression for some heart-specific genes;
however, expression of all of the heart-specific genes in
nonbeating areas was highly variable (Fig. 1C–E). Based on
these criteria, it was surmised that areas picked could be
labeled beating or nonbeating.
RT-PCR was used first to determine PKC isotype gene
expression in beating and nonbeating areas. Primer se-
quences for each isotype were obtained from Pauken and
Capco (2000), except for , , and 
 (, GenBank Accession
No. AF325507; , Accession No. NM_008859; 
, Accession
No. BF022712). RT-PCR of pluripotent colonies of ES cells
(capable of forming chimeric mice if injected into blasto-
cysts) resulted in detection of all isotypes of PKC (Fig. 1F).
These same results were seen in nonbeating areas of EBs on
day 8 of cardiomyocyte culture (Fig. 1G). Beating areas
containing similar cell counts as nonbeating areas, however,
showed a reduction in PKC isotype expression, specifically
PKC , 1/2, , , and 
 (Fig. 1G and H). PKC and  were
detectable (just above minimal detection levels) in two of
five experiments, suggesting that they were expressed at
very low levels. Evidence using semiquantitative PCR using
tubulin primers to amplify tubulin transcripts as control
revealed that the low levels of PKC and  seen in Fig. 1H
represent low levels of gene expression (Fig. 1H, and data
not shown). Note that Fig. 1C and F represent the same
RNA sample, Fig. 1D and G represent the same sample, and
Fig. 1E and H represent the same sample.
Protein analysis of beating and nonbeating areas does
not fully recapitulate gene expression
To confirm the level of gene expression found by RT-
PCR, the overall level of protein expression in beating and
nonbeating areas was analyzed. The most significant change
observed by Western blot analysis was the complete ab-
sence of PKC in beating areas. Also observed was a
decrease in PKC, , 
, and  expression (Fig. 2A–J).
Interestingly, at no time (up to D13) after induction of
beating did the levels of , , 
, and  protein expression
completely disappear as they did for PKC. Except for
PKC and , all other isotype expression remained rela-
tively unchanged between beating and nonbeating areas. In
contrast to PKC, levels of PKC protein increased in
beating areas when compared with nonbeating areas (Fig.
2E), suggesting that this PKC isotype might be necessary
for ES cells to differentiate into beating cardiomyocytes.
The results from RT-PCR are summarized in Table 1, and
Western blot data are summarized in Table 2.
Immunofluorescent analysis of PKC isotypes within EBs
closely mimics immunoblot analyses of beating and
nonbeating areas
Further resolution of PKC isotype expression in beating
and nonbeating areas required immunofluorescence micros-
copy. Because molecular and biochemical analyses of
PKC, , and  showed the most dramatic changes between
beating and nonbeating areas, we focused primarily on their
localization. Antibodies directed against PKC (polyclonal
or monoclonal) followed by fluorescently labeled secondary
antibodies resulted in a strong, highly specific signal within
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cells comprising beating areas (Fig. 3A and C). This high
level of staining was rarely seen in nonbeating areas (Fig.
3A and C). Confocal microscopy clearly showed distinct
staining for PKC on the plasma membrane in newly dif-
ferentiated, beating cardiomyocytes (12–18 h post onset
of beating; Fig. 3A–D). Beating areas were identified by
using an antibody directed against troponin C (cardiac-
specific; Fig. 3B, inset) and by morphology (Fig. 1A and B,
Fig. 1. Distinct areas in embryoid bodies, each plated in 1 well of a 24-well dish, differentiated into beating cardiomyocytes. Beating began approximately
2 days after plating. (A) Figure shows an area prior to beating. (B) The same area as in (A) during beating. Inset shows a different focal plain, in which a
demarcation between beating and nonbeating areas is visible (arrows). (C) RT-PCR of cardiac-specific genes is shown from undifferentiated colonies of ES
cells, nonbeating areas from EBs (D), and beating areas from EBs (E). All cardiac genes tested were always amplified from RNA isolated from beating areas.
Some heart-specific genes are present in nonbeating areas; however, their expression was highly variable from experiment to experiment. (F–H) The RT-PCR
results of PKC isotypes from undifferentiated ES colonies (F), nonbeating areas from EBs (G), and beating areas from EBs (H). Note the reduction of PKC
isotype expression in beating areas, specifically PKC, , , , , and 
 ( and  were barely detectable in 4 separate RT-PCR experiments). Note that (C)
and (F) are from the same RNA sample, (D) and (G) are from the same RNA sample, and (E) and (H) are from the same RNA sample.
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inset). While some nonbeating areas were positive for
PKC, the staining was mostly cytoplasmic and at consid-
erably lower levels than beating areas (Fig. 3A and C).
PKC, however, was not detected in cells comprising
beating areas (Fig. 3E and F), but was detected in nonbeat-
ing areas at low levels (Fig. 3F, inset). Antibodies to PKC
showed similar results as antibodies to PKC, while other
isotypes (i.e., , , , , ) showed little difference in
expression between beating and nonbeating areas (data not
shown).
Functional analysis of specific PKC isotypes: does
specific inhibition of PKC isotypes enhance or inhibit the
beating phenotype of EBs?
Taken together, gene and protein expression data from
beating and nonbeating areas suggested a role for three of
the PKC isotypes: PKC, , and . These three isotypes
showed the most significant changes in both gene and pro-
tein levels; interestingly, at opposite ends of the spectrum.
While PKC levels (protein) rose, PKC levels (gene and
protein) disappeared, and PKC levels were significantly
downregulated. It must be noted that these data were ob-
tained from areas that were already beating, albeit only
hours after beating had started. However, this fact raised a
key question concerning the physiological relevance of the
findings. Were these changes in PKC isotype expression
causative or simply an effect resulting from beating? To
solve this problem, we utilized specific isotype inhibitors to
PKC, , and .
These inhibitors are the amino acid sequences that bind
to their respective RACKs (receptor for activated protein
kinase C; Johnson et al., 1996; Ron et al., 1995). They
inhibit kinase activity by inhibiting translocation to the
specific membranes where they become active (Bandyoadhyay
et al., 1997; Eicholtz et al., 1993; Gray et al., 1996; Johnson
et al., 1997; Ron et al., 1995; Ward and O’Brian, 1993).
When the polypeptides are myristolated, they become li-
Fig. 2. Western blot analysis of each PKC isotype compared beating and
nonbeating areas. (A–J) A representative view of each isotype. All blots
were stripped and reprobed with anti-tubulin to measure levels of protein
loaded. A reduction in protein levels for , , , , and 
 was observed in
beating areas when compared with their respective nonbeating areas. Lev-
els of PKC were undetectable in beating areas, while levels of PKC
increased. Levels of protein for PKC, , and  remained relatively the
same in both areas. No other bands were identified on any Western
performed. Postage stamp-sized images are shown only to save space.
Table 1
RT-PCR analysis of EBs
PKC isotype Undifferentiated Nonbeating areas Beating areas
alpha ()   
beta ()   
gamma ()   
delta ()   
epsilon ()   
zeta ()   
theta ()   
iota (
)   
lambda ()   
mu (	)   
Table 2
Western analysis of EBs
PKC isotype Undifferentiated* Nonbeating areas Beating areas
alpha ()   
beta ()   
gamma ()   
delta ()   
epsilon ()   
zeta ()   
theta ()   
eta ()   
iota (
)   
lambda ()   
* , not shown.
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pophilic and are capable of incorporating into membranes
within the cell where they directly interact with and shut
down the specific PKC isotype (Eicholtz et al., 1993; Gray
et al., 1997). They are not drugs in the same sense as
conventional PKC inhibitors (e.g., calphostin C, cheleryth-
rine, staurosporine, etc.), which can inhibit multiple kinases,
including those that are unknown, resulting in possible
misinterpretation of cellular affects.
Fig. 4A shows results from EBs that were subjected to
myristolated PKC pseudosubstrates (myr-PKC). In all ex-
periments, EBs began beating significantly sooner after in-
cubation in specific inhibitors to PKC or  when compared
with control EBs. On average, 17 and 19% of untreated and
DMSO controls, respectively, contained areas that were
beating by D9. In contrast, on D9, 65  1.3% of EBs
cultured in media containing 100 	M myr-PKC- were
beating, while 55  1.0% of those subjected to 100 	M
myr-PKC- were beating (P  0.01 for both time points
compared with controls). By day 10, over 90% (92 2.0%;
P  0.01) of the EBs treated with myr-PKC- were
beating. This high percentage of beating was never seen in
control EBs at any time during the duration of the experi-
ments. The percentage of beating control EBs peaked at
75% (84 beating/112 total EBs from 5 experiments),
which occurred on D12.
Opposite effects (fewer beating EBs compared with con-
trol) were observed in EBs subjected to a specific inhibitor
to PKC (same times as above). This significantly low
percentage (P  0.01) was evident up to culture D11, after
which, myr-PKC- treatment was not able to inhibit EBs
from forming beating areas (Fig. 4A). In fact, the effects of
myr-PKC- were completely overcome by D13, when
beating in treated EBs approached that of controls.
An amount of 100 	M of each pseudosubstrate was used
because this concentration gave maximal effects with min-
imal detriment to the cells. Fig. 4B shows the dosage effect
of each inhibitor at D10. Maximal effect was observed at
both 100 and 200 	M of each pseudosubstrate. Although
detriment to cell integrity was not observed by DIC micros-
copy at 200 	M (EBs in myr-PKC or - still beat at that
concentration for days), we chose to use 100 	M of each
pseudosubstrate throughout our experiments to minimize
any possible side effects.
Next, we analyzed more specifically the characteristics
of beating in treated and untreated EBs. As described above
for controls, an entire EB does not beat. Only distinct areas
within an EB differentiate into cardiomyocytes that beat.
However, each area that beats does so with distinct rhythm
at relatively constant rates for at least 7–10 days.
EBs subjected to myr-PKC- were not only found to
beat sooner than controls, it was quite evident that they
contained up to three times the number of distinct beating
areas compared with control EBs (Fig. 4C). On D9 in all
control EBs, the number of beating areas averaged 0.25 per
EB; that is, after 24–36 h of culture, some EBs had 1
beating area, while the majority had 0. EBs that were sub-
jected to myr-PKC-, however, averaged over 1.5 beating
areas per EB (1.55  0.3 beating area/EB, P  0.01) 24 h
after treatment. By D10 of culture, EBs subjected to myr-
PKC- had 3 more beating areas than control EBs
(0.75  0.1 vs 2.65  0.03, P  0.01). This difference
surpassed 3 when compared with control EBs subjected to
DMSO carrier alone. By day 12 of culture, a significant
increase in beating areas within control EBs was observed
compared with the previous day; however, at no time did the
number of beating areas in controls match that of EBs
incubated in myr-PKC- (Fig. 4C). Remarkably, on occa-
sion (10 EBs overall), by D14–D15 of incubation in
media containing myr-PKC-, all of the beating areas
would be observed beating in unison beginning at a single
point and traversing over 80–90% of the EB. This phenom-
enon was never seen in control EBs.
Conversely, EBs incubated in myr-PKC- showed a
significant decrease in the average number of beating areas
per EB throughout the duration of the experiment when
compared with controls (1.4 0.8 vs 3.75 0.6; P 0.01;
Fig. 4C); however, inhibiting PKC using up to 200 	M
myr-PKC- did not result in complete inhibition of beat-
ing, especially at later time points of incubation (Fig. 4C).
Next, we determined the rate of each foci as measured by
using videomicroscopy (see Materials and methods). Inhib-
itors to PKC and  did not significantly stray from control
rates (Fig. 5A). Antagonizing PKC did show a significant
decrease in beat rate when compared with controls (55 
3.1 beats/min control vs 35  2.1 beats/min PKC inhibi-
tion at day 9 of differentiation; P  0.01; Fig. 5A and B,
chart); however, not as significant as the general PKC in-
hibitor calphostin C (used at concentrations specific for
PKC), which suggested that PKC isotypes other than , ,
and , might be necessary for complete differentiation of ES
cells into cardiomyocytes. However, an equally relevant
explanation for the effects of calphostin C could be that this
drug may inhibit other unknown kinases that are needed for
cardiomyocyte differentiation, function, or both.
Fig. 3. Beating areas were analyzed by confocal microscopy using antibodies to cardiac troponin and the PKC isotypes  and . (A) intense staining of PKC
was evident in beating areas with most staining highly localized to cells within beating areas (three arrows). Nonbeating areas were positive for PKC, but
at significantly lower levels. (B) Beating areas were identified by anti-troponin (inset shows higher magnification of troponin staining). (C) Double labeling
(A, B) with anti-troponin and PKC clearly shows PKC residing in beating cells. (D) High-magnification view of a beating area shows distinct labeling of
PKC on the plasma membrane of beating cells (arrowheads). Small microdomains of PKC are also visible (asterisks). (E) Beating area represented by
anti-troponin staining. (F) Same cells as in (E), except red signal shows lack of staining for PKC. Inset in (F) shows a random nonbeating area staining
positively for PKC. Line in (F), 75 	m in (A–C), 10 	m in (D) and 25 	m in (E) and (F).
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Areas induced to beat by PKC isotype-specific antagonists
are similar to naturally occurring beating areas
Although the cells that populate beating areas within EBs
have been repeatedly shown to mimic cardiomyocytes in
virtually every detail (formation of pacemaker and working
atrial/ventricular cardiomyocytes; Hescheler et al., 1997;
Metzger et al., 1996; Meyer et al., 2000; Wobus et al., 1991;
Xu et al., 1998), it was possible that cells comprising beat-
ing areas within EBs subjected to PKC isotype-specific
inhibitors were not as closely related to naturally occurring
cardiomyocytes. To determine more precisely whether car-
diomyocyte content matched that of antagonist-induced
beating areas, we compared isolated, naturally beating areas
to isolated antagonist-induced beating areas by Western blot
analysis using antibodies directed against cardiac-specific
components. Fig. 6 demonstrates four key markers of car-
diomyocytes: -cardiac actin, cardiac-specific troponin T/C,
GATA-4, and dihydropyridine (DHP) receptor (L-type
Ca2 channel a2 subunit). We also used an antibody to
SM22, a muscle-specific, calponin-related protein expressed
in cardiomyocytes in vivo beginning at embryonic day 9 in
mice (Li et al., 1996). In each case, little or no difference
was observed between antagonist-induced and naturally oc-
curring beating areas (Fig. 6).
Downregulation of PKC and  is a final step for ES cell
differentiation into cardiomyocytes
From the combined RT-PCR, Western blot, immunoflu-
orescence, and inhibition data described above, we deter-
mined that either PKC, , or both were instrumental in
determining cardiomyocyte beating activity of ES cells
within EBs. Furthermore, we surmised that many more ES
cells within an EB are primed to become cardiomyocytes
than actually arise (in controls); however, they do not beat
because PKC, , or both are not downregulated. This
interpretation stemmed from the fact that the PKC gene
and protein disappeared in newly beating areas within EBs,
and when prematurely inhibited, produced EBs that beat
sooner and contained many more beating areas when com-
pared with controls. While PKC protein was not com-
pletely gone in beating areas, inhibiting it in entire EBs via
myr-PKC- did result in phenotypic changes similar to
EBs subjected to myr-PKC- (Fig. 4), suggesting that its
downregulation was involved in the upregulation of beating
during cardiomyocyte differentiation. However, from the
above experiments in which EBs were subjected to myr-
PKC or -, one specific observation was made: While we
had controlled beating temporally, we had not done so
spatially; that is, all beating areas in control EBs or EBs
treated with myr-PKC- and - arose spontaneously.
To determine more accurately whether downregulation
of PKC or  was a last step for cardiomyocyte differenti-
ation, we established a set of experiments whereby PKC or
 was inhibited temporally and spatially in EBs. To do so,
we incubated 75–100 	m diameter, anionic or cationic
beads (depending on the charge of the peptide) in either
myr-PKC- or myr-PKC-, after which they were placed
onto nonbeating EBs. Beating around beads soaked in myr-
PKC- was increased by almost 36% when compared with
areas surrounding control beads soaked in DMSO or media
(Fig. 7, and Table 3). Beads soaked in myr-PKC- resulted
in 43% more areas that were beating adjacent to beads than
control (DMSO) EBs (13%). Unfortunately, combining
these two inhibitor peptides on the same beads to see
whether higher percentages of beating areas were attainable
was not possible because they had different ionic charges
(myr-PKC- is 6, and myr-PKC- is 2).
From these data, we determined that a large proportion of
ES cells within specifically differentiated EBs are capable
of beating; however, many do not beat because the PKC
gene in those ES cells is not suppressed. Downregulation of
the PKC gene, or more likely PKC protein, also appears
to contribute to beating most likely in a PKC-independent
manner. Consequently, we propose that downregulation of
PKC at the gene and protein level and PKC at the protein
level are key events for final specification of cardiomyocyte
differentiation from ES cells.
Discussion
In this investigation, we gain insight into the function of
specific PKC isotypes as they regulate cardiomyocyte dif-
ferentiation. A strength of this investigation was the use of
ES cells as a model system primarily because they could be
manipulated to form embryoid bodies (EBs), which repro-
ducibly give rise to beating cardiomyocytes. Another key
advantage for having used the ES cell model system is that
many genetic and molecular details of cardiomyocyte dif-
ferentiation have been well documented (Hescheler et al.,
1997; Metzger et al., 1996; Meyer et al., 2000; Xu et al.,
1998). That said, however, few investigations have docu-
Fig. 4. Functional analysis of specific PKC isotypes. Does specific inhibition of PKC isotypes enhance or inhibit the beating phenotype of EBs? Each EB
was plated at 12:00 p.m. in a well of a 24-well plate after 7 total days of growth in suspension (see Hescheler et al., 1997 for timing). The same EBs were
subjected to treatments at 12:00 p.m. the next day (D8). Only well-attached EBs showing no signs of beating were treated. (Graph A) EBs began beating
sooner when subjected to specific inhibitors of PKC and  when compared with controls. In contrast, EBs subjected to a specific inhibitor to PKC resulted
in fewer beating EBs compared with control. (Graph B) The concentration of myr-PKC- was dose-dependent. Effects peaked at 100 	M. Little or no cell
damage was observed by using DIC microscopy. (Graph C) Cardiomyocytes beat in distinct foci within an EB. EBs subjected to specific inhibitors of PKC
and  showed a dramatic increase (compared with control) in the number of beating foci as soon as 12 h posttreatment (midnight D9). However, EBs subjected
to a specific PKC antagonist had significantly fewer beating foci when compared with controls.
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mented the function of proteins in ES cells (in vitro) or
presumptive mesoderm cells (in vivo) as they differentiate
into cardiomyocytes, especially those proteins comprising
distinct signal transduction mechanisms.
This story is quite different for neonatal and adult car-
diomyocytes, where relative ease at attaining these cells has
led to the identification of numerous signal transduction
pathways (Li et al., 2001; Lim et al., 2001; Mizukami et al.,
2000); one of which, the PKC superfamily signaling path-
way, has been extensively investigated and described in
adult cardiac tissue from a myriad of species (Bogoyevitch
et al., 1992; Clerk et al., 1995; Gray et al., 1997; Ping et al.,
1997; Roman et al., 2001; Rouet-Benzineb et al., 1996;
Schreiber et al., 2001; Tanaka and Nishizuka, 1994; Xu et
al., 1998).
Some PKC isotypes appear to function in diseased hearts
to regulate recovery from problems such as short-term isch-
emia (Johnson et al., 1996; Mizukami et al., 2000; Rouet-
Benzineb et al., 1996), while others have been implicated in
hypertrophic responses (Bowling et al., 1999; Jalili et al.,
1999). However, because most investigations have focused
on PKC in adult cardiac tissue, only a relative handful of
details exist concerning how the PKC superfamily functions
to control cardiomyocyte development. Based on previous
evidence demonstrating the significance of PKC isotypes in
adult cardiomyocytes, we hypothesized that specific PKC
isotypes found in ES cells function to control the cardio-
myocyte differentiation pathway.
In undifferentiated ES cells (capable of forming chimeric
mice if injected into blastocysts), we found that all 11 PKC
isotypes tested were expressed at the gene and protein
levels. This expression pattern persisted in ES cells within
embryoid bodies (EBs) up to days 7–8 of culture, prior to
any noticeable differentiation into cardiomyocytes. How-
ever, soon after beating was observed, PKC gene and pro-
tein expression in cells comprising beating areas was dra-
matically, and relatively quickly, altered. Six of 11 PKC
isotypes found in nonbeating areas were either downregu-
lated to low levels of expression (, ) or were suppressed
altogether (, , , 
). Interestingly, protein expression did
not fully recapitulate gene expression. PKC
 and  gene
expression, for example, was undetectable in beating areas,
while their respective protein levels remained relatively the
same between beating and nonbeating areas. This finding
did not come as a complete surprise, though, as PKC and
 isotypes have been shown to persist for days without gene
expression in other systems, such as in early preimplanta-
tion mammalian embryos (unfertilized egg through early
blastocyst stage; Pauken and Capco, 2000). It appears that
some PKC proteins are more stable, or are simply not
targeted for degradation as quickly as others (i.e., PKC).
At the other end of the spectrum, PKC protein levels
were dramatically increased in beating areas when com-
pared with nonbeating areas as determined by Westerns.
This isotype was the only one to show such a dramatic
increase in protein expression. Interestingly, Xu et al.
(1999) showed a similar result in P19 cells that had been
differentiated into cardiomyocytes.
Using confocal microscopy, we confirmed further the
increased levels in PKC in beating areas; however, striking
new evidence showed a distinct localization pattern for
PKC within microdomains clearly visible on the mem-
brane of newly beating cardiomyocytes. These microdo-
mains of PKC were reminiscent of those found in stimu-
Fig. 5. The rate of each foci was measured by using photodiodes connected to a videomicroscope. (A) Inhibitors to PKC and  did not stray from control
rates. Antagonizing PKC did show a significant decrease in beat rate when compared with controls, a result duplicated by the general PKC inhibitor
calphostin C (used at concentrations speculated to be specific for PKC). (B) Raw data of a chart recording from an inhibitor experiment show similar beat
rates for wild type EBs and EBs subjected to PKC-specific inhibitor (data for myr-PKC- is not shown), while EBs subjected to PKC-specific inhibitor
(or calphostin C, not shown) resulted in areas that beat much more slowly than controls.
Fig. 6. Beating areas induced by antagonists to PKC or  were compared
with naturally occurring beating areas by Western blot analysis. In each
blot, lane 1 represents randomly obtained nonbeating areas. Lane 2 repre-
sents isolated, naturally occurring beating areas. Lanes 3 and 4 represent
isolated beating areas from EBs subjected to PKC and  antagonists,
respectively. Note: Troponin C and SM22 are from the same Western blot
that was stripped and reprobed between analyses. Also note: The bottom
band in the Troponin C Western blot is the gel front.
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lated adult cardiomyocytes in which PKC was found
localized to caveolae (Rybin et al., 1999). The significance
of this interaction between PKC and caveolae is not fully
understood; however, it has been speculated that these mi-
crodomains are meeting places for activated PKC isoforms
and their targets (Rybin et al., 1999). Further investigation
is underway to understand in more detail the significance of
this phenomenon in ES cells as they differentiate into car-
diomyocytes.
Understanding expression levels of a gene and protein
before, during, and soon after stem cells differentiate into a
subsequent cell type is important for determining how spe-
Fig. 7. Spatiotemporal analysis of beating in EBs was accomplished by using ionic beads. (A) The number of beating cells surrounding a bead was calculated
as percents, quantified, and charted. By D10, approximately 25% of the beads soaked in myr-PKC or  inhibitors were attached to beating cells, while only
8% of the controls showed similar effects. This difference was amplified three fold by D12. (B–E) Two beads soaked in myr-PKC- are observed moving
together and then apart as the surrounding cardiomyocytes beat. The four panels are from a 30-s movie, whereby individual frames capture two consecutive
beats at the midpoint of beating and the midpoint of relaxation. The four images represent a 2-s interval.
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cific components control a differentiation process; however,
in most cases, left to stand alone, these data can only
provide correlative explanations. That said, gene and pro-
tein expression should be considered an important first step
when determining protein function. This inference holds
true for the PKC pathway primarily because it exists as a
superfamily of kinases, each with potentially different func-
tions within the cell.
Fortunately, overcoming the complex nature of decipher-
ing a mechanism for PKC isotypes within cells was recently
made possible with the development of isotype-specific
PKC inhibitors (Bandyoadhyay et al., 1997; Eicholtz et al.,
1993; Gray et al., 1996; Johnson et al., 1997; Ron et al.,
1995; Ward and O’Brian, 1993). Using these specific inhib-
itors on ES cells before, during, and after, they were differ-
entiated into cardiomyocytes began to provide a mechanis-
tic view into the function of specific PKC isotypes in this
system.
As noted above, PKC protein levels rose dramatically
soon after ES cells differentiated into cardiomyocytes. From
these initial data, we surmised that, if PKC was inhibited,
either some or all aspects of cardiomyocyte differentiation
would also have been inhibited. We found that diminishing
PKC activity significantly delayed the onset of beating in
EBs. Its inhibition also delayed the development of beating
areas, and those that did develop beat at a significantly
slower rate compared with controls.
PKC has been implicated as being an integral compo-
nent for protecting adult heart tissue from ischemic injury
(Gray et al., 1997; Johnson et al., 1996). If inhibited using
a PKC specific inhibitor (similar to the one used in this
report), two observations within the ischemic area of the
adult heart have been made: hypoxic preconditioning is
abolished and the rate of cardiomyocyte beating is de-
creased (Gray et al., 1997). Consequently, one interpretation
of PKC function in adult cardiac tissue is that, when
necessary, it promotes cardiomyocyte regeneration. A sim-
ilar interpretation might be made in ES cells as they differ-
entiate along the cardiac pathway. If PKC is inhibited prior
to and during cardiomyocyte differentiation, a distinct and
significant inhibition of cardiomyocyte development and
beat rate is observed, thus delaying the initial generation of
cardiomyocytes. Interestingly, this delay in cardiomyocyte
production is overcome with time, suggesting that PKC
may not serve as the primary component for differentiation.
Instead, PKC most likely serves as an amplifying signal
that combines with other components to temporally control
final aspects of cardiac differentiation.
In contrast to PKC gene and protein upregulation in
beating areas, expression of the PKC and  genes was
significantly downregulated. Most interesting was the com-
plete downregulation of the PKC gene and protein. It was
the only isotype tested that was found to be completely
downregulated. We tested the physiological significance of
PKC and  downregulation in ES cells within EBs by
subjecting them to specific inhibitors of PKC or . The
rationale behind this set of experiments was to determine
whether these isotypes functioned as a critical, final signal-
ing event in the differentiation of nonbeating ES cells into
beating cardiomyocytes. The results of these experiments
demonstrated three novel findings: (1) EBs subjected to
PKC or  antagonists resulted in a temporal shift in the
onset of beating. Almost 90% of the EBs showed signs of
beating in as little as 2 days of incubation in PKC antag-
onist. This was almost 40% sooner than control EBs. (2)
Significantly more EBs were found beating over time when
compared with untreated EBs. In addition, we were able to
keep EBs beating up to 20 days in culture if they were
treated with PKC antagonist for at least the first week of
culture. In comparison, control EBs usually stopped beating
after 10 days of culture. (3) Significantly more beating areas
within EBs treated with either PKC or  antagonists were
observed when compared with controls. It must be noted
that, while we counted an EB as beating or not, usually the
entire EB did not beat. Distinct areas within the EB beat,
typically doing so independently of each other. Remarkably,
on occasion, by D14–D15, of those incubated in media
containing PKC antagonist, all of the beating areas would
be observed beating in unison beginning at a single point
and traversing over 80–90% of the EB. This phenomenon
was never seen in control EBs.
Taken together, we conclude that PKC and  must be
shut down in order for beating to ensue in a differentiating
ES cell. We also conclude that many more cells within an
EB are primed to become cardiomyocytes; however, they do
not begin beating because PKC and/or  are not down-
regulated. The signal controlling this downregulation is not
known; however, experiments are underway to determine
possible clues.
Previous investigations (and noted above) noticed that
beating occurs randomly in areas within EBs (Hescheler et
al., 1997; Xu et al., 1998). While EBs incubated in myr-
PKC or - resulted in an increased number of areas that
temporally beat sooner, the previous observation held true;
all beating areas arose arbitrarily. To determine whether
beating could be controlled spatially as wells as temporally,
we soaked cationic or anionic beads in each inhibitor, fol-
lowed by placing them onto EBs. A secondary rationale for
this set of experiments was to acquire further evidence to
show that PKC or  downregulation was a critical event
for ES cells within EBs to differentiate into cardiomyocytes.
Table 3
Spatial analysis of beating after 72 h
Agent No. beads analyzed No. beads surrounded by
beating cells
Media 455 45 (10%)
DMSO 476 64 (13%)
PKC 620 347 (49%)*
PKC 1069 641 (60%)*
* Statistically significant compared with controls, P  0.01.
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We found that 40% more beads soaked in either myr-
PKC or - were surrounded by beating cardiomyocytes
when compared with areas surrounded by beads soaked in
media alone or DMSO. These results suggested that, not
only could beating be controlled temporally, it could also be
controlled spatially. Granted, not all the beads soaked in
inhibitor were surrounded by nascent cardiomyocytes as
other cell types can differentiate from ES cells within EBs.
However, a 40% increase over baseline controls suggested
that many areas within an EB are primed to become cardi-
omyocytes. Thus, we conclude that these areas fail to beat
because PKC or  is not downregulated.
Why would PKC and/or  need to be downregulated to
initiate beating in EBs? It is highly likely that a substrate(s) for
PKC and/or  directly controls the beating phenotype in
cardiomyocytes. It also is highly likely that control of their
specific downregulation or inactivation is under delicate regu-
lation. In vivo, presumptive mesoderm that will form the heart
must differentiate under the strictest parameters, yet do so
quickly. Setting up all the necessary components for beating,
save one or two (e.g., PKC or ), would ensure and expedite
spatiotemporal differentiation of cardiomyocytes as the heart
undergoes morphogenesis. In support of this premise, Takeishi
et al. (1998) recently demonstrated that phosphorylation of the
myofilament regulatory protein, cardiac troponin 1, by PKC
caused considerable depression in cardiac function. Interest-
ingly, inhibition of PKC caused marked improvement of this
induced phenotype.
PKC may be performing a similar function in vitro in
EBs and in vivo in presumptive mesoderm destined to
become cardiac tissue. PKC may phosphorylate troponin 1
in differentiating ES cells, inhibiting its function within the
contractile network of cardiomyofilaments (Takeishi et al.,
1998). Alternatively, PKC may constitutively phosphory-
late the Na/H exchanger (Prigent et al., 1997), causing
decreased exchanger activity and inhibition of cardiomyo-
cyte function (beating). Studies are currently underway to
resolve this complex problem.
Interestingly, based on recent data reported from Lumel-
sky et al. (2001), Mazurova (2001), and Vogel (2002), who
have suggested using ES cells therapeutically (as well as
data presented here), a second use for the ES model system
used in conjunction with drug delivery through ionic ex-
change beads has come about: its use in investigating the
role of local gradients for differentiating ES cells along
specific pathways before they are used for treatment in certain
neurological, pancreatic, or cardiovascular diseases (Con-
dorelli et al., 2001; Hescheler et al., 1997; Lebkowski et al.,
2001; Lumelsky et al., 2001; Mazurova, 2001; Vogel, 2002).
Here, we showed that specific activators or inhibitors
localized by beads in EBs can be used to set up local
environments from which differentiation or proliferation
can be closely monitored. Beads containing reagents other
than those used in this report could easily be used on EBs.
Those ES cells adjacent to treated beads showing the correct
phenotype could then be isolated and used for therapy. The
rationale for the use of this model system is to gently push
the ES cells down the correct pathway before transplanting
them into host tissue so as to decrease or completely sup-
press the chance that an ES cell will form a teratoma.
In summary, we show that the expression of specific
PKC isotypes is significantly changed in ES cells as they
differentiate into cardiomyocytes. Furthermore, this change
appears to be a final step in the differentiation process.
While upregulation of PKC acts to amplify differentiation/
beating, PKC and  downregulation serves to promote
beating. Finally, melding classical tools (i.e., ionic ex-
change glass beads) with recently developed methods for
differentiating embryonic stem cells creates a possible novel
technique for investigating differentiation of ES cells into
cardiomyocytes as well as other cells types. Further inves-
tigations will be required to decipher the signaling events
leading to the up-and downregulation of each isotype. Using
the ES cell model system will undoubtedly be the superla-
tive tool for future investigations.
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